LatestGenetic Variant May Reduce Children's Response to Common Asthma Treatment
Health

Sanofi and Regeneron Expand Partnership Following Dupixent's Blockbuster Success

Andrew Joseph
Sanofi and Regeneron Expand Partnership Following Dupixent's Blockbuster Success
AllergiesAsthmaDermatitisEczema
Summary

Pharmaceutical giants Sanofi and Regeneron have strengthened their collaboration agreement to capitalize on Dupixent's remarkable market performance. Dupixent, a monoclonal antibody treatment targeting type 2 inflammation, has become a blockbuster drug used to treat multiple conditions including asthma, eczema, allergies, and dermatitis. The expanded partnership aims to accelerate development of new therapies and maximize the commercial potential of their existing and pipeline products. This strategic move reflects the drug's significant clinical success and growing patient demand across multiple therapeutic areas.

Stat News

Originally published on

STAT News

By Andrew Joseph

Read full article(opens in new tab)

Fetched: October 1, 2026 at 10:00 AM

Related News

More news you might be interested in

View all
Genetic Variant May Reduce Children's Response to Common Asthma Treatment
Health
Asthma

Genetic Variant May Reduce Children's Response to Common Asthma Treatment

A new study in the Journal of Allergy and Clinical Immunology reveals that children carrying a variant in the SERPINE1 gene—present in about 60% of the population—may experience reduced effectiveness from mepolizumab, a biologic medication used to treat asthma flares. This genetic variant appears to trigger increased inflammation in response to the drug, potentially limiting its therapeutic benefit. Understanding this genetic predisposition could help healthcare providers identify which children may need alternative or adjusted asthma management strategies. This finding underscores the growing importance of personalized medicine in treating pediatric asthma and optimizing treatment outcomes for affected children.

2 hours ago
Medical Xpress
AI Can Now Analyze Your Genome in 30 Minutes—But We Need Standards for Results
Health

AI Can Now Analyze Your Genome in 30 Minutes—But We Need Standards for Results

Genome analysis has been revolutionized by artificial intelligence. What once required 30 people and almost a year in 2009 can now be completed by Claude AI in just 30 minutes for approximately $5. This dramatic advancement in genomic technology offers tremendous potential for personalized medicine and disease risk assessment. However, experts emphasize that standardized protocols and quality standards are urgently needed to ensure the accuracy and clinical validity of AI-generated genomic interpretations. Without proper regulatory frameworks and professional guidelines, patients and healthcare providers may receive unreliable results that could impact medical decision-making.

2 hours ago
STAT News
Opinion: GLP-1 Weight Loss Drugs in Children Show Reassuring Results
Health
DiabetesHeart Disease

Opinion: GLP-1 Weight Loss Drugs in Children Show Reassuring Results

A transplant surgeon's research on GLP-1 receptor agonist medications in children presents reassuring safety findings. These weight loss drugs, commonly used in adults for obesity and diabetes management, could potentially prevent decades of irreversible health damage when used during childhood. Early intervention with GLP-1 medications may address childhood obesity before it leads to serious complications like heart disease and metabolic dysfunction. The study suggests that treating obesity in young patients could have long-term protective health benefits, though further research and medical oversight remain essential for pediatric use.

2 hours ago
STAT News
Major GOP Leadership Changes Coming to Key Senate Health Committees
Health

Major GOP Leadership Changes Coming to Key Senate Health Committees

Two major Senate committees that oversee critical healthcare policy are experiencing significant Republican leadership transitions. These shifts will reshape the committees responsible for decisions affecting drug regulation, Medicare, Medicaid, and public health initiatives. The leadership changes could influence how healthcare legislation is prioritized and developed in the coming congressional session. Understanding these committee composition changes is important for patients who depend on decisions made about pharmaceutical access, coverage policies, and healthcare funding.

2 hours ago
STAT News